FIELD: biotechnology.
SUBSTANCE: group of inventions refers to medicine, namely to oncology and genetics, and can be used to detect hereditary form of breast cancer (BC) in primary genetic testing. Described is a panel for determining hereditary form of breast cancer during primary genetic testing, which includes 48 pathogenic variants of genes. Also described is a method for detecting hereditary forms of breast cancer, which is realized by using the created panel. Detection of at least one of the pathogenic variants detected by the above panel in the patient testifies to the presence of the hereditary form of breast cancer. Created diagnostic panel increases the accuracy of detecting the hereditary form of breast cancer in primary genetic testing by including the most common genome-wide variants of the clinically significant (pathogenic) variants of genes associated with an increased or high risk of developing breast cancer.
EFFECT: created panel allows detecting up to 80-90% of hereditary forms of breast cancer within the framework of one diagnostic examination within the framework of primary genetic testing.
2 cl, 4 dwg, 4 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR IDENTIFYING RECESSIVE FACTORS OF GENETIC PREDISPOSITION TO BREAST CANCER | 2013 |
|
RU2535157C1 |
METHOD FOR MOLECULAR-GENETIC DIAGNOSIS OF HEREDITARY BREAST CANCER | 2019 |
|
RU2702755C1 |
METHOD OF PREDICTING A LOW RISK OF DEVELOPING BREAST CANCER IN WOMEN WITH HIGHLY PENETRATING MUTATIONS IN THE BRCA1 AND CHEK2 GENES | 2022 |
|
RU2798666C1 |
METHOD FOR PREDICTION OF GENETIC PREDISPOSITION TO BREAST CANCER | 2012 |
|
RU2522501C1 |
METHOD FOR PREDICTION OF RISK OF MALIGNANT DISEASES OF MAMMARY GLAND AND/OR OVARIES IN PATIENTS AFTER KIDNEY TRANSPLANTATION | 2023 |
|
RU2821583C1 |
METHOD OF DIFFERENTIATED USE OF DNA SEQUENCING DATA FOR PATIENTS AFTER KIDNEY TRANSPLANTATION | 2022 |
|
RU2803796C1 |
METHOD FOR DETERMINING GENETIC MARKERS FOR ASSESSING POLYGENIC RISK OF BREAST CANCER (HORMONE-NEGATIVE AND HORMONE-POSITIVE SUBTYPES) | 2020 |
|
RU2749465C1 |
METHOD FOR ANALYSING DISORDERS RELATED TO OVARIAN CARCINOMA | 2008 |
|
RU2511408C2 |
DETERMINATION OF CANCER SUSCEPTIBILITY BY IDENTIFICATION OF GENOTYPIC COMBINATIONS OF SPECIFIC VERSIONS OF CYP1B1, BRCA2 AND CHEK2 GENES | 2006 |
|
RU2470998C2 |
METHOD FOR DETERMINING GENETIC MARKERS FOR ASSESSING POLYGENIC RISK OF DEVELOPING HORMONE-POSITIVE SUBTYPE OF BREAST CANCER | 2020 |
|
RU2753002C1 |
Authors
Dates
2025-01-14—Published
2024-08-28—Filed